Dimerix Ltd (ASX:DXB, OTC:SBMJF) has completed dosing the last adult patient in its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis (FSGS), with final adult enrolment reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results